BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients
In March 2018, BIOCAD analyzed results from its Phase II study in which the original Russian IL-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed great results in the treatment of ankylosing spondylitis.
BCD-085 is an original monoclonal antibody drug blocking interleukin-17, a cytokine playing a key role in developing and maintaining various autoimmune and immunoinflammatory diseases.
The majority of psoriasis patients have serious psychological problems due to social isolation, while patients with ankylosing spondylitis may rapidly become disabled if diagnosed late or treated inappropriately. Both diseases are a serious medical and social challenge, especially because they often affect young people of working age (22 to 35 years old). The European market of IL-17 inhibitors is over $700 million and it’s going to grow to $1 677 million within next 5 years. BIOCAD expects to occupy an essential share of this perspective market.
BCD-085 has demonstrated extremely high efficacy in the recently completed Phase II clinical study. Over the first three months of treatment with Interleukin-17 inhibitor at a dose of 120 mg, significant clinical response (PASI 75) was achieved in 93% of patients with moderate to severe psoriasis who did not respond to conventional treatments. Similar improvements were seen in patients with ankylosing spondylitis who were treated with IL-17 inhibitor 120 mg: 91% of patients demonstrated clinical improvements (ASAS20) after 4 months of treatment.
Оne-year treatment with this IL-17 inhibitor resulted in a sustained improvement in psoriasis symptoms (PASI 75) in 98% of cases, with over 50% of patients having an sPGA score of 0 or 1 at the end of the observation, which refers to almost complete skin clearance. High efficacy of BCD-085 comes along with a favorable safety profile:
‘IL-17 inhibitor is a rare example of a monoclonal antibody used for the treatment of chronic diseases that has such a beneficial efficacy and safety profile,’ says Roman Ivanov, M.D., PhD, BIOCAD’s Vice-President of Research and Development. ‘We have a good reason to believe that BCD-085 will become the best-in-class interleukin-17 inhibitor. This is why we are going to initiate a phase III study in the European Union in 2019; in this study, we will compare our product head-to-head with another IL-17 inhibitor.’
Head of PR Department
Tel.: +7(812)3804933, ext. 632
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC25.9.2018 12:32 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed by a blinded independent review committee (BIRC), by more than fifty percent compared to crizotinib in adults with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor. Findings from the first interim analysis of the ALTA-1L trial will be presented during the Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC) in Toronto on Tuesday, September 25, 2018. The data were also simultaneously published online in The New England Journal of Medicine. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSC
Softomotive and Enate Partner to Help Clients Orchestrate Workflows across Their RPA Ecosystem25.9.2018 12:15 | Pressemelding
Softomotive, a leading Robotic Process Automation (RPA) vendor, has announced a strategic partnership with Enate, the pioneering Robotic Service Orchestration (RSO) provider. Together, Softomotive and Enate will allow business enterprises of all sizes to go further and faster with their automation programmes, achieving greater efficiency through orchestration of workflows between human employees and software robots. This partnership will offer Softomotive and Enate’s mutual customers the flexibility to orchestrate workflow between humans and bots whether the enterprise is using just Softomotive bots or more than one RPA provider. “As the RPA market matures, we are finding more and more clients are relying on more than one RPA provider, ” said Marios Stavropoulos, Softomotive’s CEO. “This adds an extra layer of complexity and Softomotive is all about simplifying things for our clients. This new partnership with Enate will do just that by allowing them to continue to orchestrate combined
Scientist.com Adds Experienced Drug Hunter Mark Herbert to Management Team25.9.2018 12:06 | Pressemelding
Scientist.com, the life science industry’s leading online marketplace for outsourced research, announced today the appointment of Mark Herbert to its senior leadership team. As the company’s chief business officer, he will focus on continuing the company’s rapid growth and expansion into new research areas and countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005077/en/ Scientist-entrepreneur Mark Herbert brings his strong scientific background and business experience to Scientist.com as new Chief Business Officer. (Photo: Business Wire) “The Scientist.com research sourcing platform is revolutionizing how medical research is done,” said Mark Herbert, Scientist.com’s new Chief Business Officer. “I look forward to helping establish new partnerships, expand existing partnerships and advance our goal of delivering an innovative and disruptive marketplace to the global life sciences community.” Mark has 20+ years’ e
OpenGate Capital Signs Exclusivity Agreement to Sell NAKAN to Westlake Chemical Corporation25.9.2018 12:00 | Pressemelding
OpenGate Capital, a global private equity firm, announced today that it has signed an exclusivity agreement with Westlake Chemical Corporation (NYSE: WLK), pursuant to which Westlake has made a binding offer to acquire NAKAN, a global PVC compounding solutions business headquartered in Reims, France. The transaction is valued at $265 million and is anticipated to be completed by early 2019. NAKAN has eight production facilities located in China, France, Germany, Italy, Japan, Mexico, Spain and Vietnam, as well as a world-class research facility in France and application laboratory in the United States. NAKAN products are used in a wide-variety of applications by customers in the automotive, building and construction, and medical industries. OpenGate Capital acquired NAKAN in 2015, through the acquisition of Ivy Group, during the firm’s pre-fund, legacy investment period. Ivy Group, formerly known as Kem One Innovative Vinyls, was acquired through a French administration process that or
The 2018 IDN World Report Findings Show Negative IDN Growth in 201725.9.2018 11:24 | Pressemelding
The 2018 IDN World Report findings have been published to idnworldreport.eu. The major findings from the report are: As at December 2017, 7.5 million IDNs were registered, a drop of 14% since December 2016. A major factor in the reduction in global IDN numbers was a change of policy by the Vietnam ccTLD, which resulted in a loss of nearly 1 million .vn second level IDNs. Excluding the impact of .vn, the underlying trend is negative growth of -5%, distributed mainly across second level ccTLDs. IDNs comprise 2% of the world’s domains, a percentage that has remained fairly static since at least 2012. The data in this report include IDNs across both ccTLDs and gTLDs, both at the first and second level. Distribution patterns of IDN registrations are different from those of traditional, ASCII domain names. IDN registrations are highest in Asia and Pacific region. The script of IDNs registered throughout the world strongly correlate to the languages spoken in different countries and territori
Michael Kors Holdings Limited to Be Renamed Capri Holdings Limited25.9.2018 11:00 | Pressemelding
Michael Kors Holdings Limited (NYSE:KORS), a global fashion luxury group, announced today that a definitive agreement has been signed to acquire all of the outstanding shares of Italian luxury fashion house Gianni Versace S.p.A. for a total enterprise value of Euro 1.83 billion or approximately US$2.12 billion. Versace, long recognized as one of the world’s leading luxury fashion companies, is synonymous with Italian glamour and style. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005557/en/ L-R: Jonathan Akeroyd, Donatella Versace, John D. Idol. (Photo: Rahi Rezvani) John D. Idol, Chairman and Chief Executive Officer of Michael Kors Holdings Limited, said, “The acquisition of Versace is an important milestone for our group. Versace was founded in 1978. For over 40 years, Versace has represented the epitome of Italian fashion luxury, a testament to the brand’s timeless heritage. We are excited to have Versace as part